University of Pittsburgh

Children’s Hospital of Pittsburgh of UPMC

Children’s Hospital of Pittsburgh of UPMC
4401 Penn Ave
Pittsburgh, PA 15224
United States
Call 412-692-7241 Email this location

University of Pittsburgh is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Dorothy Becker, MD, the TrialNet team at University of Pittsburgh is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis. Our center is located at the Children's Hospital of Pittsburgh of UPMC.

Our Team

Principal Investigators 
Professor of Pediatrics, Diabetes Research Director
Dorothy J. Becker has been internationally recognized for her work in the treatment and prevention of diabetes in children. Dr. Becker is professor of pediatrics at the University Of Pittsburgh School Of Medicine and a pediatric endocrinologist with over 30 years of experience. Dr. Becker’s clinical and research focus is diabetes and the application of new therapies in this area. Among her many achievements, Dr. Becker has received the McEllroy Award from the University of Pittsburgh Medical Alumni Association, the Founder’s Award from the Midwest Society of Pediatric Research and the Award for Outstanding Contribution to Diabetes in Youth from the American Diabetes Association. She also is a member of the western Pennsylvania board of directors of the Juvenile Diabetes Association and has been invited to lecture audiences around the world.
Co-Investigator, Clinical Director, Assistant Professor of Pediatrics
Heba Ismail is an Assistant Professor of Pediatrics in the Division of Pediatric Endocrinology and is currently the Clinical Director of Diabetes at Children’s Hospital of Pittsburgh of UPMC. Amongst her many research interests, a large interest of hers is the work that is being done with Type 1 Diabetes TrialNet. Her main research focus is on understanding the pathogenesis and natural progression to Type 1 Diabetes.
Co-Investigator, Associate Professor of Pediatrics, Associate Professor of Epidemiology, Director of Diabetes Program
Ingrid Libman is the director of the diabetes program at Children’s Hospital of Pittsburgh and an Associate Professor in the Division of Pediatric Endocrinology and Diabetes at Children’s Hospital of Pittsburgh of UPMC. She also holds a secondary appointment in the Department of Epidemiology, Graduate School of Public Health, University of Pittsburgh. Her scientific interests focus on the etiology, prevention and treatment of diabetes in childhood, with particular emphasis on the effect of obesity and insulin resistance in type 1 diabetes mellitus (T1DM).
Research Coordinators 
Study Coordinator
Kelli DeLallo is a Research Nurse at the University of Pittsburgh. She is currently the TrialNet study coordinator, overseeing daily activities of the study. She has been involved in diabetes research for over 10 years and has prior experience in pediatric nursing.
Affiliate Coordinator
Karen Riley is a Research Nurse who works on Type 1 Diabetes TrialNet. She has over 30 years of nursing and diabetes experience. She has been employed in the past the study coordinator and now currently works with our affiliate sites on orientation, training and oversight of the 15 affiliates that Pittsburgh currently has.
Recruitment Coordinator
David Groscost is a Research Nurse at the University of Pittsburgh. His main research study is Type 1 Diabetes TrialNet, which is aimed at prevention and delaying progression of type 1 diabetes. His previous experience was as a lab manager for 6 years prior to nursing school. He is currently the recruitment coordinator at this clinical center.
"We all know someone on some personal level who is affected by diabetes, and knowing how it is a major life changer and the amount of work involved to manage it, we are absolutely dedicated to finding a cure!” Hebatullah Ismail, MD

Regional Affiliates


Akron Childrens Hospital
One Perkins Square, Akron, OH 44308


Johns Hopkins Diabetes Center
601 N. Caroline Street, Baltimore, MD 21287


MODEL Clinical Research
6535 N. Charles St., Suite 400N, Baltimore, MD 21204


CAMC Health Education and Research Institute, Inc
830 Pennsylvania Ave., Suite 104, Charleston, WV 25302


University of Virginia Health System
1215 Lee St, Barringer Hall Room 4443, Charlottesville, VA 22908


Cincinnati Childrens Hospital Med Center
3333 Burnet Ave., MLC 7012, Cincinnati, OH 45229


Cleveland Clinic Foundation
9500 Euclid Ave., Cleveland, OH 44195


Case Western Reserve University
11100 Euclid Ave., Cleveland, OH 44106


The Ohio State University Wexner Medical Center
543 Taylor Ave, Columbus, OH 43203


Central Ohio Pediatric Endocrinology & Diabetes Srv
55 Dillmont Dr. Ste 100, Columbus, OH 43235


Childrens Research Institute
555 S. 18th Street Suite 6E, Columbus, OH 43205


Childrens Hospital of Philadelphia
34th St & Civic Center Blvd., Philadelphia, PA 19104


Allegheny-Singer Research Institute
4800 Friendship Ave, Ste N221, 2nd Floor, Pittsburgh, PA 15224


Childrens National Medical Center
111 Michigan Ave., NW, Washington, DC 20010


DuPont Hospital for Children - Nemours Childrens Clinic
1600 Rockland Road, Wilmington, DE 19803

Research Studies

The following studies are actively recruiting participants. Please click on the study title to learn more. For those interested in participation, contact us for more information.
Risk Screening

Pathway to Prevention

If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.


Prevention Study


TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.



We are testing the drug teplizumab to see if it can delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.



Long-Term Investigative Follow-Up in TrialNet (LIFT)

Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.